VANCOUVER, Nov. 18 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO - News) is pleased to report that iCo-009, the company's oral Amphotericin B program, has been accepted for a poster presentation at the American Association of Pharmaceutical Scientist (AAPS) Meeting in Atlanta, GA.
